



PDL Drug Class Review Announcement October 6, 2009

Drug Classes to be Reviewed:

Newer generation antidepressants and the following classes used to treat pulmonary hypertension (Phosphodiesterase inhibitors, Prostanoids, and Endothelin Antagonists) will be reviewed for the Colorado Medicaid Preferred Drug List. In addition, the antiemetics, proton pump inhibitors, and triptan medications are being re-reviewed. The medications listed below and all of their respective formulations, dosage forms, and strengths will be reviewed.

Request for Dossier:

Submit a dossier by September 14, 2009 for clinical review at the Pharmacy and Therapeutics Committee meeting on October 6, 2009. Include a brief synopsis of the clinical information, one to four pages in length, for P&T dissemination. **If a dossier has been previously submitted, only submit a synopsis of the clinical information unless new information is available.**

Mail, Fax, or email dossier and synopsis to:
Department of Health Care Policy & Financing
1570 Grant Street
Denver, CO 80203
Attn: Jim Leonard
Fax: 303-866-3552
jim.leonard@state.co.us

Request for Supplemental Rebate Offers:

Submit two copies of executed supplemental rebate agreements by September 30, 2009. The supplemental rebate agreement template is posted on the PDL webpage. All fields highlighted in gray must be completed on the template. The performance period for these agreements is **January 1, 2010 – December 31, 2010**. Please use a **separate Attachment A (Net Cost Offer) for combination products**.

Mail offers to:
Department of Health Care Policy & Financing
1570 Grant Street
Denver, CO 80203
Attn: Tom Leahey

Pharmacy & Therapeutics (P&T) Committee Meeting:

The P&T Committee will review clinical data and will receive public comments and testimony related to the drug classes being reviewed. They will then make a clinical recommendation concerning these medications. The P&T Committee meeting will be held on October 6, 2009 from 1:00 p.m. - 5:00 p.m. at 225 E. 16th Avenue, Denver, Colorado, first floor conference room.

Public Comments:

Public comments concerning the drugs subject to review need to be submitted by October 1, 2009. The P&T Committee will review public comments before the meeting.

Email comments to: pdl@state.co.us

or

Mail comments to:

Colorado Department of Health Care Policy and Financing

Pharmacy Benefits Section

1570 Grant St

Denver, CO 80203

Attn: Jim Leonard

Drugs Subject to Review:**Newer Generation Antidepressants**

Brand Name	Generic Name
Aplenzin ER	bupropion ER
	bupropion
	bupropion SR (12 hour)
	bupropion XL (24 hour)
Celexa	citalopram
	citalopram
Cymbalta	duloxetine
Effexor	venlafaxine
Effexor XR	venlafaxine XR
	fluoxetine
	fluvoxamine
Lexapro	escitalopram
Luvox	fluvoxamine
Luvox CR	fluvoxamine controlled release
	mirtazapine
	nefazodone
	paroxetine
Paxil	paroxetine
Paxil CR	paroxetine controlled release
Pexeva	paroxetine
Pristiq	desvenlafaxine
Prozac	fluoxetine
Prozac Weekly	fluoxetine
Remeron	mirtazapine
	sertraline
	venlafaxine
	venlafaxine extended release
Wellbutrin	bupropion

Wellbutrin SR	bupropion SR (12 hour)
Wellbutrin XL	bupropion XL (24 hour)
Zoloft	sertraline

Phosphodiesterase Inhibitors

Brand Name	Generic Name
Adcirca	tadalafil
Revatio	sildenafil

Prostanoids

Brand Name	Generic Name
	epoprostenol
Flolan	epoprostenol
Remodulin	treprostinil
Tyvaso	treprostinil
Ventavis	iloprost

Endothelin Antagonists

Brand Name	Generic Name
Letairis	ambrisentan
Tracleer	bosentan

Antiemetics

Brand Name	Generic Name
Aloxi	palonosetron
Anzemet	dolasetron
Emend	aprepitant
	granisetron
Kytril	granisetron
	ondansetron
Sancuso	granisetron
Zofran	ondansetron

Proton Pump Inhibitors

Brand Name	Generic Name
Aciphex	rabeprazole
Kapidex	dexlansoprazole
Nexium	esomeprazole
	omeprazole
	pantoprazole
Prevacid	lansoprazole
Prilosec	omeprazole

Prilosec OTC	omeprazole
Protonix	pantoprazole
Zegerid	omeprazole/sodium bicarbonate

Triptans and Combinations

Brand Name	Generic Name
Amerge	naratriptan
Axert	almotriptan
Frova	frovatriptan
Imitrex	sumatriptan
Maxalt	rizatriptan
Relpax	eletriptan
	sumatriptan
Treximet	sumatriptan/naproxen
Zomig	zolmitriptan